NASDAQ:ORGS Orgenesis (ORGS) Stock Price, News & Analysis $0.35 +0.28 (+400.00%) As of 11:07 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsInsider TradesSEC Filings About Orgenesis Stock (NASDAQ:ORGS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Orgenesis alerts:Sign Up Key Stats Today's Range$0.00▼$0.3550-Day Range$0.03▼$0.6752-Week Range$0.00▼$1.00Volume778 shsAverage Volume1,005 shsMarket Capitalization$1.81 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Orgenesis Inc. is a biotechnology company focused on developing and enabling cell and gene therapies. The company works on autologous cell therapies, which use a patient’s own cells, and on technologies designed to support the processing, manufacturing and delivery of these therapies. Its activities include the development of proprietary therapeutic programs and the Orgenesis POCare platform. POCare is intended to provide decentralized, point-of-care capabilities for cell and gene therapy manufacturing, helping clinical and healthcare sites produce treatments closer to the patient under controlled processes. Orgenesis was founded in 2011 and has pursued partnerships and operations across the United States, Europe and Israel. Vered Caplan, a co-founder of the company, has served as its chief executive officer. The company’s work combines therapeutic development with manufacturing infrastructure intended to support broader adoption of advanced cell and gene therapies.AI Generated. May Contain Errors. Read More Receive ORGS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Orgenesis and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ORGS Stock News HeadlinesOrgenesis (NASDAQ:ORGS) Stock Falls 5.2% - Here's What HappenedOctober 6, 2026 | americanbankingnews.comOrgenesis Shareholders Approve Major Charter and Stock IncreaseJune 4, 2026 | theglobeandmail.comHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. One day it's a ceasefire, the next it's bombs again. The back and forth may be masking a bigger story most investors are missing. See the real reason this conflict may never fully end.October 14 at 1:00 AM | Banyan Hill Publishing (Ad)Orgenesis Issues Alpha Warrant in New Financing DealJanuary 26, 2026 | tipranks.comOrgenesis Subsidiary Secures Convertible Loan AgreementSeptember 16, 2025 | tipranks.comOrgenesis Director Ashish Nanda ResignsAugust 25, 2025 | tipranks.comOrgenesis Faces Multiple Leadership Resignations in AugustAugust 20, 2025 | msn.comOrgenesis Delays Filing of Quarterly ReportMay 16, 2025 | tipranks.comSee More Headlines ORGS Stock Analysis - Frequently Asked Questions How have ORGS shares performed this year? Orgenesis' stock was trading at $0.15 on January 1st, 2026. Since then, ORGS shares have increased by 133.3% and is now trading at $0.35. How were Orgenesis' earnings last quarter? Orgenesis Inc. (NASDAQ:ORGS) released its quarterly earnings data on Friday, August, 11th. The company reported ($1.50) EPS for the quarter, missing the consensus estimate of $0.60 by $2.10. The company earned $6.98 million during the quarter. When did Orgenesis' stock split? Orgenesis shares reverse split before market open on Wednesday, September 25th 2024.The 1-10 reverse split was announced on Monday, September 23rd 2024. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, September 24th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. Does Orgenesis have any subsidiaries? The following companies are subsidiaries of Orgenesis: Koligo Therapeutics, and Tamir Biotechnology Inc. How do I buy shares of Orgenesis? Shares of ORGS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Orgenesis own? Based on aggregate information from My MarketBeat watchlists, some other companies that Orgenesis investors own include NVIDIA (NVDA), Redhill Biopharma (RDHL), SoFi Technologies (SOFI), BigBear.ai (BBAI), IonQ (IONQ), Taiwan Semiconductor Manufacturing (TSM) and Micron Technology (MU). Company Calendar Last Earnings8/11/2023Today10/14/2026Next Earnings (Estimated)11/11/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:ORGS CIK1460602 Webwww.orgenesis.com Phone(480) 659-6404FaxN/AEmployees150Year Founded2008Profitability EPS (Trailing Twelve Months)($11.51) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$55.36 million Net Margins-3,827.81% Pretax Margin-3,931.93% Return on EquityN/A Return on Assets-130.18% Debt Debt-to-Equity RatioN/A Current Ratio0.07 Quick Ratio0.07 Sales & Book Value Annual Sales$662 thousand Price / Sales2.73 Cash FlowN/A Price / Cash FlowN/A Book Value($6.58) per share Price / Book-0.05Miscellaneous Outstanding Shares5,169,000Free Float4,527,000Market Cap$1.81 million OptionableNo Data Beta2.86 Social Links 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free Report This page (NASDAQ:ORGS) was last updated on 10/14/2026 by MarketBeat.com Staff. From Our PartnersINSANE DRONE FOOTAGENew drone footage shows a mysterious factory rising at one of Elon Musk's most secure facilities, cleared and ...Paradigm Press | SponsoredWhy Some AI Stocks Already Surged Over 300 PercentJason Bodner's system flagged Nvidia before a 7000 percent run, Super Micro Computer before a 2600 percent run...Brownstone Research | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredA new income category is drawing serious money - here's whyForbes recently called a new category of exchange-traded income funds a 'golden era,' and Bloomberg noted the ...Investors Alley | SponsoredI'm giving you a space stock today. Free.On December 8th, $600 billion in frozen SpaceX stock comes loose. Dylan Jovine says one simple purchase in any...Behind the Markets | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | SponsoredUrgent: Invest In ‘Elon’s iPhone’ Before July 22ndEarly Apple investors saw peak gains as high as 7,537% after the iPhone launched. Now, multiple insider source...StocksToTrade | SponsoredDo this before December or regret itPorter Stansberry believes President Trump will use the December G20 Summit in Miami to unveil a radical monet...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Orgenesis Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Orgenesis With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
